Compare · ARAY vs DXCM
ARAY vs DXCM
Side-by-side comparison of Accuray Incorporated (ARAY) and DexCom Inc. (DXCM): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ARAY and DXCM operate in Medical/Dental Instruments (Health Care), so they compete in similar markets.
- DXCM is the larger of the two at $33.10B, about 1594.4x ARAY ($20.8M).
- Over the past year, ARAY is down 90.9% and DXCM is up 29.2% - DXCM leads by 120.2 points.
- ARAY has been more active in the news (8 items in the past 4 weeks vs 6 for DXCM).
- DXCM has more recent analyst coverage (25 ratings vs 4 for ARAY).
- Company
- Accuray Incorporated
- DexCom Inc.
- Price
- $0.15-8.79%
- $86.05-1.93%
- Market cap
- $20.8M
- $33.10B
- 1M return
- -37.01%
- -2.13%
- 1Y return
- -90.92%
- +29.24%
- Industry
- Medical/Dental Instruments
- Medical/Dental Instruments
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2007
- 2005
- News (4w)
- 8
- 6
- Recent ratings
- 4
- 25
Accuray Incorporated
Accuray Incorporated designs, develops, and sells radiosurgery and radiation therapy systems for the treatment of tumors in the body in the Americas, Europe, the Middle East, India, Japan, Africa, and rest of the Asia Pacific region. The company offers the CyberKnife System, a robotic stereotactic radiosurgery and stereotactic body radiation therapy system used for the treatment of various types of cancer and tumors in the body. Its CyberKnife System automatically tracks, detects, and corrects for tumor and patient movement in real-time during the procedure, as well as enables the delivery of precise, high dose radiation while patients breathe normally. The company also offers the TomoTherapy System, including the Radixact System, which consists of an integrated and versatile radiation therapy system used for the treatment of a range of cancer types. It markets its products in the United States directly, as well as through sales organizations, sales agents, and group purchasing organizations; and directly, as well as through distributors and sales agents in Europe, Asia, and South America to hospitals and stand-alone treatment facilities. The company was incorporated in 1990 and is headquartered in Sunnyvale, California.
DexCom Inc.
DexCom, Inc., a medical device company, focuses on the design, development, and commercialization of continuous glucose monitoring (CGM) systems in the United States and internationally. The company offers its systems for use by people with diabetes, as well as for use by healthcare providers. Its products include DexCom G6, an integrated CGM system for diabetes management; Dexcom G7, a next generation G7 CGM system; and Dexcom Share, a remote monitoring system. DexCom, Inc. has a collaboration and license agreement with Verily Life Sciences LLC and Verily Ireland Limited to develop next-generation CGM products. The company markets its products directly to endocrinologists, physicians, and diabetes educators. DexCom, Inc. was founded in 1999 and is headquartered in San Diego, California.
Latest ARAY
- SEC Form DEF 14A filed by Accuray Incorporated
- SEC Form 8-K filed by Accuray Incorporated
- SEC Form 4 filed by Accuray Incorporated
- SEC Form 3 filed by Accuray Incorporated
- Accuray Announces Stockholder Approval of Key Financing-Related Proposals and Appointment of New Independent Director
- SEC Form 8-K filed by Accuray Incorporated
- SVP Chief Financial Officer Pervaiz Ali was granted 19,811 shares and covered exercise/tax liability with 8,915 shares, increasing direct ownership by 3% to 366,259 units (SEC Form 4) (for tax liability)
- Accuray and Samsung NeuroLogica Advance Volumetric Imaging Collaboration for the Accuray CyberKnife® Platform
- SEC Form DEFA14A filed by Accuray Incorporated
- SEC Form EFFECT filed by Accuray Incorporated
Latest DXCM
- Landmark Dexcom CONNECT Study Published in The New England Journal of Medicine, Redefining the Standard of Care for People with Type 2 Diabetes Not on Insulin
- Barclays initiated coverage on Dexcom with a new price target
- Dexcom Schedules Third Quarter 2026 Earnings Release and Conference Call for October 29, 2026 at 4:30 p.m. Eastern Time
- Dexcom U Enters Season 5 With a Record Roster and Evidence That Diabetes Stigma Among Young Athletes Is Fading
- EVP Chief People & Culture Off Stern Sadie sold $220,975 worth of shares (2,565 units at $86.15) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 123,478 units (SEC Form 4)
- Dexcom Publishes New Report During EASD 2026 on Type 2 Diabetes Revealing Critical Opportunity for Global Diabetes Care
- EVP Chief Legal Compliance Off Brown Michael Jon sold $142,868 worth of shares (1,700 units at $84.04) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 99,885 units (SEC Form 4)
- Director Augustinos Nicholas sold $679,769 worth of shares (8,089 units at $84.04) as part of a pre-agreed trading plan (SEC Form 4)
- DexCom Inc. filed SEC Form 8-K: Leadership Update, Regulation FD Disclosure, Financial Statements and Exhibits
- Dexcom Promotes Jereme Sylvain to Chief Operating Officer